With a $290M Deficit, Vermillion May Need to Explore Tests Beyond OVA1, Evaluating Funding Options

"To become profitable, the company may need to complete development of additional key diagnostic tests, obtain the US Food and Drug Administration approval and successfully commercialize those products in addition to the OVA1 Test," Vermillion stated in its most recent quarterly financial statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.